Breakthroughs in weight loss medication keep coming, which means it’s only a matter of time before employees ask about new or updated coverage. But shedding pounds and keeping them off requires more than medicine.
One of the latest GLP-1 advancements is Eli Lilly’s new oral obesity drug, Orforglipron, which during testing helped reduce weight and blood sugar levels in type 2 diabetes patients, with effectiveness on par with popular injectible weight loss drugs such as Ozempic and Wegovy.
